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We describe the occurrence of measles in an 18 month-
old patient in Sicily, Italy, in March 2015, who received 
the first dose of a measles-containing vaccine seven 
days before onset of prodromal symptoms. Measles 
virus infection was confirmed by PCR and detection of 
specific immunoglobulin; viral genotyping permitted 
the confirmation of a vaccine-associated illness. The 
patient had a concurrent influenza virus infection, dur-
ing a seasonal epidemic outbreak of influenza.
Case description
In early March 2015, measles-mumps-rubella-varicella 
zoster (MMRV) vaccine was administered to an appar-
ently healthy 18-month-old child living in Sicily, Italy. 
Seven days later, the child presented to the family pae-
diatrician with fever (40.1 °C), catarrhal cough, runny 
nose and eyelid oedema. Macular rash appeared over 
the body two days later, starting on the trunk and then 
spreading to the neck and face. By day 13, the rash 
was fading, but due to the persistence of symptoms, 
the child was admitted to a children’s hospital and 
reported as a possible case of vaccine-related measles 
to the Epidemiology Department of the Regional Public 
Health.
The local health authority carried out an epidemiologi-
cal investigation: a standard measles notification form 
was sent to the regional health authorities and imme-
diately forwarded to the Ministry of Health and to the 
Infectious Diseases Epidemiology Unit of the National 
Institute of Health. No direct link was identified with 
other measles cases in the community and the fam-
ily had no history of travel outside Sicily. Moreover, 
contact investigation revealed no household mem-
bers or pre-school contacts with symptoms consistent 
with measles. One of the child’s parents developed 
influenza-like illness (ILI) symptoms (fever (> 38 °C) 
and cough, which lasted for three consecutive days) 
one day after administration of MMRV vaccine to the 
patient.
Urine and throat swab specimens were collected from 
the child and submitted to the Regional Reference 
Laboratory in Palermo for nucleic acid-based testing for 
measles, mumps, rubella and varicella zoster viruses 
and genotyping of any detected viruses. Given that 
this patient with suspected vaccine-associated mea-
sles developed symptoms during a seasonal epidemic 
outbreak of influenza viruses, and taking into account 
reports of morbilliform rash associated in patients 
with influenza B who tested negative for measles virus 
infection [1,2], testing was also requested for influenza 
and other respiratory viruses.
While no viruses could be detected in the urine speci-
men, measles, influenza A(H3N2) and respiratory syn-
cytial viruses were detected in the throat swab.
On day 17, the patient’s symptoms resolved without 
complications and the patient was discharged from 
hospital (Figure).
Measles virus was detected in throat swabs taken on 
days 17, 19, 21 and 25, but no influenza or other res-
piratory viruses were detectable in these specimens.
Measles virus was not detected on day 28 from a 
throat swab and urine specimen. A blood sample was 
taken at this time for serological testing for measles, 
mumps, rubella and varicella zoster viruses. A time line 
of events is shown in the Figure.
Seroconversion following MMRV immunisation was 
evaluated through the detection of specific measles, 
rubella, mumps and varicella zoster IgM and IgG anti-
bodies by chemiluminescent immunoassay (CLIA) (mea-
sles virus: IgM = 3.1 arbitrary units (AU)/mL, IgG > 300 
2 www.eurosurveillance.org
AU/mL; mumps virus: IgM = 1.3 AU/mL, IgG = 78.9 AU/
mL; rubella virus: IgM = 1.97 AU/mL, IgG = 18.0 interna-
tional units (IU)/mL; varicella zoster: IgM = 0.71 AU/mL, 
IgG = 271.8 mIU/mL).
The measles virus was determined to be the Schwarz 
vaccine strain, genotype A, MVs/Palermo.ITA/12.15 [A] 
(VAC) [3] by sequence analysis of the genome.
Laboratory investigations
Serological and nucleic acid-based tests were per-
formed for surveillance of measles and rubella, and 
genotype determination at the Regional Reference 
Laboratory of Palermo, formerly a member of the 
national network for influenza surveillance and geno-
typing (INFLUNET).
For the detection of specific measles, rubella, mumps 
and varicella zoster IgM and IgG antibodies, com-
mercial CLIA tests were used (LIAISON (DiaSorin) and 
VITROS (Ortho Clinical Diagnostics)), which have the 
following cut-off values: measles IgM ≥ 1.0; measles 
IgG ≥ 13.5; mumps IgM ≥ 1.0; mumps IgG ≥ 10.0; rubella 
IgM ≥ 1.2; rubella IgG ≥ 15.0; varicella zoster IgM ≥ 1.0; 
varicella zoster IgG ≥ 100.0.
Throat swabs and the sediment of urine samples were 
tested using a real-time PCR instrument (QuantStudio 7 
Flex Real-Time PCR system, Applied Biosystems), using 
specific primer/TaqMan probe sets for measles [4], 
mumps [5], rubella [4] and varicella zoster [6,7] viruses 
after extraction of total RNA using QIAmp Viral RNA 
Mini Kit (Qiagen).
Measles genotyping was conducted to distinguish wild-
type from vaccine-associated measles viral strains. PCR 
products, targeting either the N gene or the H gene [8], 
were obtained from throat swab and sequenced using 
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems).
Figure
Time line of symptoms and physical signs in a child with post-vaccine measles and concomitant influenza, case 
management, specimen collection and laboratory results, Sicily, Italy, March 2015
MMRV: measles-mumps-rubella-varicella zoster; neg: negative; pos: positive. 
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SuperScript One-Step RT-PCR kit with Platinum Taq 
(Invitrogen) were used for both endpoint reverse tran-
scription RT-PCR and real-time RT-PCR reactions.
Sequences were confirmed as measles virus following 
comparison with the BLAST algorithm and they were 
phylogenetically analysed to assign genotype and clus-
ter. The sequences were identified as Schwarz vaccine 
strain (genotype A) and were submitted to GenBank 
(accession numbers KR262162 (gene N) and KR262161 
(gene H)).
Background
In Italy, vaccination against measles is included in 
the national vaccination schedule. Two doses of mea-
sles-mumps-rubella (MMR) vaccine have been rec-
ommended in all regions since the early 1990s [9], 
sometimes in association with varicella vaccination. 
The first dose is given at 13–15 months-old and the 
second at the age of 5–6 years [10].
In accordance with the national measles elimination 
plan [11], an enhanced surveillance system was intro-
duced in 2007 [12] with the aim of improving timeliness, 
completeness of case reporting and case investigation, 
including laboratory confirmation of diagnosis and 
viral genotyping.
As the incidence of wild-type measles decreases in 
countries with high levels of vaccination coverage, 
vaccine-associated cases could be misreported [13,14], 
suggesting that there is a need to improve the ability to 
distinguish between vaccine-associated measles and 
‘true’ wild-type measles virus infection [15].
Post-marketing surveillance of vaccines is manda-
tory in Italy and adverse reactions observed after the 
administration of vaccines are reported through the 
national pharmacovigilance network. According to the 
latest data available [16], these are mainly represented 
by fever, skin rash and febrile seizures, while post-
vaccination viral shedding is a very uncommon event, 
which has been rarely documented so far [17,18].
Discussion
With an estimated more than 500 million doses admin-
istered in over 60 countries since the 1970s, the benefit 
of measles vaccination in preventing illness, disability 
and death appear unchallengeable [19,20].
Moreover, vaccine safety is annually validated by accu-
rate post-marketing surveillance of adverse reactions 
conducted by the Italian Medicines Agency (AIFA). As 
for other live attenuated vaccines, adverse reactions 
following MMR or MMRV immunisation rarely present 
with clinically significant illness [16]: such illness is 
indistinguishable from wild-type measles. In this con-
text, the reference laboratory for molecular surveillance 
plays a fundamental role in measles virus characteri-
sation, through viral sequencing and genotyping, in 
order to promptly differentiate between wild-type and 
vaccine-related strains [14,18].
In this report, we documented the pharyngeal excretion 
of the Schwarz measles vaccine virus in an apparently 
healthy child with a febrile rash after measles vaccina-
tion and with laboratory-confirmed influenza A(H3N2) 
coinfection.
On the basis of our data, some points can be noted.
Firstly, although unlikely, measles after MMRV vaccina-
tion is possible, and this can mimic wild-type infection, 
leading to potential measles case misclassification. 
The application of molecular techniques for viral gen-
otyping is helpful to correctly classify a case and to 
drive the decisions of public health authorities at the 
local level.
Secondly, this is the first report of a measles case 
with concurrent influenza and respiratory syncyt-
ial virus detection: we cannot exclude the possibility 
that the co-presence of other viral natural infections 
in a very young child, showing a slight hypogamma-
globulinaemia in serum protein electrophoresis, may 
have favoured, or even determined, the occurrence 
of vaccine-related measles virus in pharyngeal secre-
tions. Unfortunately, the parent showing ILI symptoms 
was not tested for influenza virus, making us unable to 
assess, although very likely, an intrafamilial transmis-
sion of influenza virus infection.
Notably, virus excretion was demonstrated over a 
25-day period after vaccination, which is longer than 
previously reported [17,21,22]. Interference with 
other coinfecting viruses or a defective host immune 
response could play a role in this unexpected persis-
tence of measles virus, although this hypothesis will 
require further investigation.
Thirdly, virus excretion was repeatedly detected in the 
throat, but not in urine sediment. This finding partially 
contrasts with World Health Organization (WHO) guid-
ance for laboratory diagnosis for measles virus infec-
tion, which suggests to test preferentially for the virus 
in the sediment of urine samples that have been col-
lected within at least five days after the onset of rash 
[23]. In the case presented here, in accordance with 
WHO guidance, matched urine and throat specimens 
were collected on the fifth day after the onset of macu-
lar rash. 
Detection of measles virus in respiratory samples up to 
16 days after the onset of rash suggests that other host 
cell pathways or viral mechanisms, potentially related 
to other concomitant viral infections, might be respon-
sible for such an event. However, also in this case, fur-
ther studies are necessary to better explain such an 
anomaly.
In conclusion, development of measles in individuals 
who have received MMR or MMRV vaccine is a possible, 
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although extremely rare, event. Therefore, especially in 
geographical areas with a low incidence of measles, 
maintenance of efficient molecular surveillance sys-
tems and the improvement of the timeliness of both 
case reporting and virus genotyping is of paramount 
importance, to ensure correct differentiation between 
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